Ticagrelor vs clopidogrel in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention
Catheterization and Cardiovascular Interventions — Li Y, Li J, Qiu M, et al. | January 18, 2022
In acute coronary syndrome (ACS) patients undergoing complex percutaneous coronary intervention (PCI), a significantly lower risk of ischemic events was noted in relation to treatment with ticagrelor compared with clopidogrel, while the risk of major bleeding was comparable between the two drugs.
An all-comers PCI registry was used to assess the effectiveness as well as safety of ticagrelor vs clopidogrel in patients with ACS undergoing complex PCI.
Of participants, 4,373 (35.2%) and 8065 (64.8%) had dual antiplatelet therapy based on ticagrelor and clopidogrel, respectively.
In the ticagrelor-treated group, significantly lower incidences of composite ischemic events (before propensity score matching [PSM]: 1.74% vs 2.84%; after PSM: 1.50% vs 2.65%) and all-cause death (before PSM: 1.23% vs 2.12%; after PSM: 1.09% vs 1.81%) were reported, compared to the clopidogrel-treated group.
No significant difference in Bleeding Academic Research Consortium types 2, 3, and 5 bleeding was found between groups.